Clinical trials: Optic Nerve Disorders, open to volunteers
Open Angle Glaucoma, Primary Open Angle Glaucoma
Topical Insulin for Glaucoma (TING2)
This study evaluates the safety and preliminary efficacy of topical sterile human insulin eye drops (EYED-002) in patients with open-angle glaucoma.
- Conditions
- Open Angle Glaucoma, Primary Open Angle Glaucoma, Low Tension Glaucoma, Pigmentary Glaucoma
- Trial name
- NCT07619482
- Testing
- EYED-002 Low Dose (721 U/mL topical insulin), EYED-002 High Dose (1442 U/mL topical insulin), EYED-002 (highest tolerated dose, 12-month)
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Stanford University
Uveal Melanoma, Metastatic
Tebentafusp and Roginolisib in Uveal Melanoma to Prolong T-cell Homeostasis
This is a combination study of Tebentafusp and the PI3Kdelta inhibitor, Roginolisib
- Trial name
- TRIUMPH (NCT07203391)
- Testing
- roginolisib
- Where
- 2 sites in Australia
- Volunteers
- 8 people
- Sponsor
- St Vincent's Hospital, Sydney
Progressive Supranuclear Palsy(PSP), Dementia With Lewy Bodies (DLB)
Digital Health Technologies for Progressive Supranuclear Palsy and Dementia With Lewy Bodies
Progressive supranuclear palsy (PSP), mild cognitive impairment with Lewy bodies (MCI-LB), and Dementia with Lewy Bodies (DLB) are severe neurodegenerative diseases that cause significant motor impairment impacting daily…
- Conditions
- Progressive Supranuclear Palsy(PSP), Dementia With Lewy Bodies (DLB), PSP, Lewy Body Dementia (LBD)
- Trial name
- NCT07240805
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- BioSensics
Uveal Melanoma
Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma
This is a randomized, multi-center, open-label study of adjuvant darovasertib in participants with non-metastatic uveal melanoma (OptimUM-11)
- Trial name
- NCT07804186
- Testing
- Darovasertib, Crizotinib (Xalkori)
- Where
- 13 sites in United States, Canada
- Volunteers
- 450 people
- Sponsor
- IDEAYA Biosciences
Neuro-Ophthalmology, Optic Neuropathies
Optic Nerve Head Evaluation Through Multimodal Blood Flow Analysis: a Prospective Observational, Multi-center Study
OCT-A and eco-colordoppler are technologies which enable optic nerve head (ONH) blood perfusion detection. The aim of the study is to assess ONH vascular and structural components in optic neuropathies with and without ONH edema…
- Conditions
- Neuro-Ophthalmology, Optic Neuropathies, Optic Atrophy, Hereditary, Leber, Optic Neuropathy, Anterior Ischemic
- Trial name
- FlowONH (NCT07075887)
- Volunteers
- 70 people
- Sponsor
- Barboni
Demyelinating Diseases of the Central Nervous System (DDC)
Demyelinating Diseases of the Central Nervous System Registry for Patients With Traditional Chinese Medicine (DATE-TCM)
Demyelinating Diseases of the Central Nervous System Registry for Patients with Traditional Chinese Medicine (DATE-TCM) is an observational study aiming to better define the multidimensional (epidemiologic, demographic and…
- Trial name
- NCT05415579
- Testing
- Traditional Chinese medicine (TCM)
- Volunteers
- 2,000 people
- Sponsor
- Dongzhimen Hospital, Beijing
MS (Multiple Sclerosis), NMO Spectrum Disorder (NMOSD)
Multiple Sclerosis Versus Neuromyelitis Optica Spectrum Disorder
The aim of this work is to do a detailed comparison between multiple sclerosis and Neuromyelitis Optica Spectrum Disorder due to delicate similarities between both diseases and wide rang of management and follow up of the patients
- Trial name
- NCT07304960
- Volunteers
- 100 people
- Sponsor
- Assiut University
Advanced Solid Tumors
Safety and Efficacy Study in Adults With Advanced Solid Tumors Receiving REGN13089-M404-M2980, an Antibody-drug Conjugate That Targets MET Protein on Tumors
This study will test a Regeneron drug called REGN13089-M404-M2980 ("study drug") to see if it can help treat previously treated, advanced solid tumors (tumors that have grown and spread to different areas of the body).
- Trial name
- NCT07863024
- Testing
- REGN13089-M404-M2980
- Volunteers
- 320 people
- Sponsor
- Regeneron Pharmaceuticals
Uveal Melanoma
Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma
This is a phase II open-label, single-arm, multi-center study of tebentafusp in HLA- A*0201 positive previously untreated (1L) untreated metastatic uveal melanoma (mUM) with an integrated circulating tumor DNA (ctDNA) biomarker.
- Trial name
- NCT06070012
- Testing
- Tebentafusp
- Where
- 4 sites in United States
- Volunteers
- 44 people
- Sponsor
- Diwakar Davar
Neuromyelitis Optica Spectrum Disorders, Multiple Sclerosis
Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/ BCMA（QT-019C） in Patients With r/ r Neurological Autoimmune Diseases
This is an open label, single-site, dose-escalation study in up to 15 participants with relapsed or refractory Neurological Autoimmune Diseases.
- Conditions
- Neuromyelitis Optica Spectrum Disorders, Multiple Sclerosis, Myasthenia Gravis
- Trial name
- NCT07392528
- Testing
- QT-019C
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Tianjin Huanhu Hospital
Retinal Disease, Age-Related Macular Degeneration
Stem Cell Ophthalmology Treatment Study II
This study will evaluate the use of autologous bone marrow derived stem cells (BMSC) for the treatment of retinal and optic nerve damage or disease.
- Conditions
- Retinal Disease, Age-Related Macular Degeneration, Retinitis Pigmentosa, Stargardt Disease
- Trial name
- SCOTS2 (NCT03011541)
- Testing
- Arm 1
- Where
- 4 sites in United States, Austria and 1 more
- Volunteers
- 500 people
- Sponsor
- MD Stem Cells
Thyroid Eye Disease, TED, Graves Ophthalmopathy
Teprotumumab N01 Versus Methylprednisolone After Urgent Orbital Decompression for Dysthyroid Optic Neuropathy
This study aims to evaluate the efficacy and safety of sequential Teprotumumab N01 compared with intravenous methylprednisolone (IVMP) after urgent orbital decompression in patients with dysthyroid optic neuropathy (DON).
- Conditions
- Thyroid Eye Disease, TED, Graves Ophthalmopathy, Optic Neuropathy
- Trial name
- NCT07594912
- Testing
- Teprotumumab N01, Intravenous Methylprednisolone (IVMP)
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Sun Yat-sen University
Esotropia
Botulinum Toxin Injection Versus Prism Treatment in Small-angle Acute Acquired Concomitant Esotropia
This is a single-center, prospective, randomized controlled trial evaluating type A botulinum toxin injection and prism therapy for the treatment of small-angle acute acquired concomitant esotropia.
- Trial name
- NCT06714877
- Testing
- prism treatment group, botulinum toxin group
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Eye & ENT Hospital of Fudan University
Glaucoma
Optic Nerve Head Strain in Non-glaucoma Subjects
Persons who do not have glaucoma will have pictures taken of the optic nerve with a standard camera before and 2 weeks after starting to take a daily glaucoma eye drop to lower eye pressure.
- Trial name
- NCT07425535
- Testing
- Latanoprost (0.005%)
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Demyelinating Diseases
Use of a Portable Pupillometer to Detect Optic Nerve Impairment in Patients With Suspected Multiple Sclerosis
In the diagnosis work-up of inflammatory disorders of the central nervous system (CNS), the assessment of optic nerve impairments, even in the absence of clinical symptoms, is now systematic, as it may shorten the time to…
- Trial name
- IRIS (NCT07837050)
- Testing
- Pupillometry measures
- Volunteers
- 100 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Brain Neoplasm, Intracranial Pressure Increase
Non-invasive Intracranial Pressure Monitoring in Brain Tumor Patients
This research protocol focuses on the pre- and post-operative evaluation of ICP using non-invasive methods, particularly in the context of surgery for brain tumor removal.
- Trial name
- NCT07286396
- Testing
- Ocular Sonography
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Tanta University
Intermittent Strabismus, Exotropia Intermittent
Visual Therapy for Intermittent Strabismus
Intermittent strabismus is a condition in which the eyes occasionally become misaligned, affecting binocular vision, depth perception, and quality of life.
- Conditions
- Intermittent Strabismus, Exotropia Intermittent, Esotropia Intermittent
- Trial name
- ViT(I)S (NCT07563959)
- Testing
- Visual Therapy
- Volunteers
- 30 people
- Sponsor
- Universitat Politècnica de Catalunya
Multiple Sclerosis, NMO Spectrum Disorder
Tongji NADs Cohort
Neurological Autoimmune Diseases (NADs) are disorders caused by abnormal immune system attacks on neural tissues, affecting multiple systems including the central nervous system, peripheral nervous system, and neuromuscular…
- Conditions
- Multiple Sclerosis, NMO Spectrum Disorder, Autoimmune Encephalitis, Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease
- Trial name
- NCT07333196
- Testing
- No active interventions
- Where
- China
- Volunteers
- 1,550 people
- Sponsor
- Tongji Hospital
MELAS Syndrome, Lebers Hereditory Optic Neuropathy With Extra Ocular Symptoms (LHON-Plus)
A Basket Clinical Study to Assess Glycerol Tributyrate in Patients With Mitochondrial Encephalopathy, Lactic Acidosis, Stroke-like Episodes (MELAS) or Leber's Hereditary Optic Neuropathy-Plus (LHON-Plus)
This is a parallel arm non-randomized dose-escalation, open-label basket exploratory phase 1 clinical trial where Mitochondrial encephalopathy, lactic acidosis, stroke-like episodes (MELAS) and Leber's hereditary optic…
- Trial name
- NCT06792500
- Testing
- Glycerol Tributyrate
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- George Washington University
Non-Arteritic Anterior Ischemic Optic Neuropathy
Efficacy and Safety of Intranasal Cenegermin in Adult Participants With Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)
This is a phase 3, randomized, multicenter, vehicle-controlled, double-masked study to evaluate the efficacy and safety of intranasal cenegermin compared with vehicle control in adult participants with NAION.
- Trial name
- NCT07453888
- Testing
- Cenegermin, Vehicle
- Where
- 38 sites in United States, Australia and 2 more
- Volunteers
- 272 people
- Sponsor
- Dompé Farmaceutici S.p.A